<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">104855</article-id><article-id pub-id-type="doi">10.26442/00403660.2022.01.201326</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Lecture</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Лекция</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Detection of paraprotein in plasma cell tumors</article-title><trans-title-group xml:lang="ru"><trans-title>Определение парапротеина при плазмоклеточных опухолях</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5440-4340</contrib-id><name-alternatives><name xml:lang="en"><surname>Rekhtina</surname><given-names>Irina G.</given-names></name><name xml:lang="ru"><surname>Рехтина</surname><given-names>Ирина Германовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, зав. отд-нием химиотерапии плазмоклеточных дискразий</p></bio><email>rekhtina.i@blood.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4966-8146</contrib-id><name-alternatives><name xml:lang="en"><surname>Mendeleeva</surname><given-names>Larisa P.</given-names></name><name xml:lang="ru"><surname>Менделеева</surname><given-names>Лариса Павловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф., рук. управления по научной и образовательной работе, зав. отд. химиотерапии парапротеинемических гемобластозов</p></bio><email>rekhtina.i@blood.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1903-2446</contrib-id><name-alternatives><name xml:lang="en"><surname>Soboleva</surname><given-names>Natalia P.</given-names></name><name xml:lang="ru"><surname>Соболева</surname><given-names>Наталья Павловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>врач клинической лабораторной диагностики централизованной клинико-диагностической лаб.</p></bio><email>rekhtina.i@blood.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5256-7066</contrib-id><name-alternatives><name xml:lang="en"><surname>Dubina</surname><given-names>Irina A.</given-names></name><name xml:lang="ru"><surname>Дубина</surname><given-names>Ирина Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>врач клинической лабораторной диагностики</p></bio><email>rekhtina.i@blood.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9630-257X</contrib-id><name-alternatives><name xml:lang="en"><surname>Pervakova</surname><given-names>Margarita Iu.</given-names></name><name xml:lang="ru"><surname>Первакова</surname><given-names>Маргарита Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>врач клинической лабораторной диагностики</p></bio><email>rekhtina.i@blood.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4998-3699</contrib-id><name-alternatives><name xml:lang="en"><surname>Lapin</surname><given-names>Sergey V.</given-names></name><name xml:lang="ru"><surname>Лапин</surname><given-names>Сергей Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, зав. лаб. диагностики аутоиммунных заболеваний</p></bio><email>rekhtina.i@blood.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center for Hematology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pavlov First Saint Petersburg State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2022</year></pub-date><volume>94</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>135</fpage><lpage>144</lpage><history><date date-type="received" iso-8601-date="2022-03-14"><day>14</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-03-14"><day>14</day><month>03</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/104855">https://ter-arkhiv.ru/0040-3660/article/view/104855</self-uri><abstract xml:lang="en"><p>Paraprotein is a laboratory biomarker of plasma cell tumors and other lymphoproliferative diseases. Its determination is necessary for diagnosing, monitoring and assessment of therapy effectiveness. The lecture presents the main methods of qualitative and quantative analysis of monoclonal proteins: gel electrophoresis, capillary electrophoresis, immunofixation and nephelometry features, possibilities and limitations are reviewed. The main sources of errors and artifacts during these studies are considered. Also the difficulties in the diagnosis and interpretation of the results of serum and urine tests are highlighted.</p></abstract><trans-abstract xml:lang="ru"><p>Парапротеин – лабораторный биомаркер плазмоклеточных опухолей и других лимфопролиферативных заболеваний, определение которого необходимо для диагностики, оценки эффективности проводимой терапии и мониторинга. В данной лекции приведены основные методы качественного и количественного анализа моноклональных белков: изложены особенности, возможности и ограничения гель- электрофореза, капиллярного электрофореза, иммунофиксации и нефелометрии. Рассмотрены основные источники ошибок и артефактов при выполнении этих исследований. Обращено внимание на трудности в диагностике и интерпретации результатов исследования сыворотки и мочи.</p></trans-abstract><kwd-group xml:lang="en"><kwd>paraprotein</kwd><kwd>multiple myeloma</kwd><kwd>plasma cell disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>парапротеин</kwd><kwd>множественная миелома</kwd><kwd>плазмоклеточное заболевание</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>WHO classification of tumours oh haematopoetic and lymphoid tissues. Ed. by Swerdlov SH, Campo E, Harris NL, et al. Revised 4th ed.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bradwell AR. Serum free light chain analysis plus hevylite. 7th ed. UK (Birmingham): The Binding Site Group, 2015.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev. 2009;30:105-11.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>García-García P, Enciso-Alvarez K, Diaz-Espada F, et al. Biclonal gammopathies: Retrospective study of 47 patients. Rev Clin Esp. 2015;215(1):18-24. DOI:10.1016/j.rce.2014.07.003</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma. Lancet Oncol. 2016;17(8):e328-46. DOI:10.1016/S1470-2045(16)30206-6</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-9. DOI:10.1200/JCO.2011.37.7614</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Keren DF, Alexanian R, Goeken JA, et al. Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. Arch Pathol Lab Med. 1999;123(2):106-7. DOI:10.5858/1999-123-0106-GFCALE</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Tate J, Caldwell G, Daly J, et al. Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Ann Clin Biochem. 2012;49:242-56. DOI:10.1258/acb.2011.011158</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Keren DF, Schroeder L. Challenges of measuring monoclonal proteins in serum. Clin Chem Lab Med. 2016;54(6):947-61. DOI:10.1515/cclm-2015-0862</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Keren D. Protein Electrophoresis in Clinical Diagnosis. London, 2003.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sørrig R, Klausen TW, Salomo M, et al. Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. PLoS One. 2017;12(12):e0188988. DOI:10.1371/journal.pone.0188988</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Fujisawa M, Seike K, Fukumoto K, et al. Oligoclonal bands in patients with multiple myeloma: Its emergence per se could not be translated to improved survival. Cancer Sci. 2014;105(11):1442-6. DOI:10.1111/cas.12527</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med. 2016;54(6):907-19. DOI:10.1515/cclm-2015-0580</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Murray DL, Ryu E, Snyder MR, Katzmann JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem. 2009;55(8):1523-9. DOI:10.1373/clinchem.2009.124461</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bergón E, Miravalles E. Estimation of serum M-protein concentration from polyclonal immunoglobulins: an alternative to serum protein electrophoresis and standard immunochemical procedures. Clin Chem Lab Med. 2008;46(8):1156-62. DOI:10.1515/CCLM.2008.232</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ramakrishnan N, Jialal I. Bence-Jones Protein. StatPearls: Treasure Island (FL), 2019.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Csako G. Immunofixation Electrophoresis for Identification of Proteins and Specific Antibodies. In: Methods in molecular biology (Clifton, NJ). United States, 2019; p. 177-201.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Booth RA, McCudden CR, Balion CM, et al. Candidate recommendations for protein electrophoresis reporting from the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group. Clin Biochem. 2018;51:10-20. DOI:10.1016/j.clinbiochem.2017.10.013</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest. 1972;51:2162-74. DOI:10.1172/JCI107023</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Solomon A. Light chains of human immunoglobulins. Meth Enzymol. 1985;116:1-121. DOI:10.1016/S0076-6879(85)16008-8</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free k and free l immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;4(9):1437-44.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Drayson M, Begum G, Basu S, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108(6):2013-9. DOI:10.1182/blood-2006-03-008953</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47:673-80.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Dispenzieri A, Kyle R, Merlini G, et al; International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215-24. DOI:10.1038/leu.2008.307</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Schild C, Wermuth B, Trapp-Chiappini D, et al. Reliability of M protein quantification: comparison of two peak integration methods on Capillarys 2. Clin Chem Lab Med. 2008;46(6):876-7. DOI:10.1515/CCLM.2008.146</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011;86(3):251-5. DOI:10.1002/ajh.21948</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317-25. DOI:10.1038/leu.2012.100</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271-80. DOI:10.1182/blood.2019000834</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Katzmann JA, Snyder MR, Rajkumar SV, et al. Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. Clin Chem. 2011;57:1687-92. DOI:10.1373/clinchem.2011.171314</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Kühnemund A, Liebisch P, Bauchmüller K, et al. Light-chain escape-multiple myeloma'- an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol. 2009;135(3):477-84. DOI:10.1007/s00432-008-0470-7</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1684-90. DOI:10.2215/CJN.02290508</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Рехтина И.Г., Менделеева Л.П., Соболева Н.П. Трудности в оценке гематологического ответа у больных множественной миеломой с диализзависимой почечной недостаточностью. Терапевтический архив. 2019;91(7):70-4 [Rekhtina IG, Mendeleeva LP, Soboleva NP. Difficulties evaluating hematological response in patients with multiple myeloma and dialysis-dependent renal impairment. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(7):70-4 (in Russian)]. DOI:10.26442/00403660.2019.07.000215</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Dimopoulos M, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544-57. DOI:10.1200/JCO.2015.65.0044</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Marron ТU, Ramanathan L, Chari A. Diagnostic utility of measuring free light chains in the cerebrospinal fluid of patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2015;15(6):e127-31. DOI:10.1016/j.clml.2015.02.028</mixed-citation></ref></ref-list></back></article>
